A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

Asuka Tsuya, Takayasu Kurata, Akihiro Tamiya, Isamu Okamoto, Shinya Ueda, Daisuke Sakai, Naotoshi Sugimoto, Koji Matsumoto, Isao Goto, Nobuyuki Yamamoto, Masahiro Fukuoka, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1-21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.

Original languageEnglish
Pages (from-to)1568-1572
Number of pages5
JournalInvestigational New Drugs
Volume31
Issue number6
DOIs
Publication statusPublished - Dec 1 2013
Externally publishedYes

Fingerprint

Cisplatin
Carcinoma
Combination Drug Therapy
Appointments and Schedules
Febrile Neutropenia
Neutropenia
Safety
Survival
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site. / Tsuya, Asuka; Kurata, Takayasu; Tamiya, Akihiro; Okamoto, Isamu; Ueda, Shinya; Sakai, Daisuke; Sugimoto, Naotoshi; Matsumoto, Koji; Goto, Isao; Yamamoto, Nobuyuki; Fukuoka, Masahiro; Nakagawa, Kazuhiko.

In: Investigational New Drugs, Vol. 31, No. 6, 01.12.2013, p. 1568-1572.

Research output: Contribution to journalArticle

Tsuya, A, Kurata, T, Tamiya, A, Okamoto, I, Ueda, S, Sakai, D, Sugimoto, N, Matsumoto, K, Goto, I, Yamamoto, N, Fukuoka, M & Nakagawa, K 2013, 'A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site', Investigational New Drugs, vol. 31, no. 6, pp. 1568-1572. https://doi.org/10.1007/s10637-013-0014-0
Tsuya, Asuka ; Kurata, Takayasu ; Tamiya, Akihiro ; Okamoto, Isamu ; Ueda, Shinya ; Sakai, Daisuke ; Sugimoto, Naotoshi ; Matsumoto, Koji ; Goto, Isao ; Yamamoto, Nobuyuki ; Fukuoka, Masahiro ; Nakagawa, Kazuhiko. / A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site. In: Investigational New Drugs. 2013 ; Vol. 31, No. 6. pp. 1568-1572.
@article{08d54db96c1e4859b3c650f0ac784b47,
title = "A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site",
abstract = "Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1-21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 {\%} and 80.4 {\%}, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 {\%}, 13.0 {\%}, and 2.2 {\%} of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.",
author = "Asuka Tsuya and Takayasu Kurata and Akihiro Tamiya and Isamu Okamoto and Shinya Ueda and Daisuke Sakai and Naotoshi Sugimoto and Koji Matsumoto and Isao Goto and Nobuyuki Yamamoto and Masahiro Fukuoka and Kazuhiko Nakagawa",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/s10637-013-0014-0",
language = "English",
volume = "31",
pages = "1568--1572",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "6",

}

TY - JOUR

T1 - A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

AU - Tsuya, Asuka

AU - Kurata, Takayasu

AU - Tamiya, Akihiro

AU - Okamoto, Isamu

AU - Ueda, Shinya

AU - Sakai, Daisuke

AU - Sugimoto, Naotoshi

AU - Matsumoto, Koji

AU - Goto, Isao

AU - Yamamoto, Nobuyuki

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1-21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.

AB - Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1-21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.

UR - http://www.scopus.com/inward/record.url?scp=84888645574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888645574&partnerID=8YFLogxK

U2 - 10.1007/s10637-013-0014-0

DO - 10.1007/s10637-013-0014-0

M3 - Article

C2 - 23975509

AN - SCOPUS:84888645574

VL - 31

SP - 1568

EP - 1572

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 6

ER -